Recently, by targeting Erb-B2 Receptor Tyrosine Kinase 2(HER2) gene, CRISPR-Cas9 has managed to inhibit cell proliferation and tumorigenicity in HER2-positive breast cancer cells, demonstrating its potency in clinical application (85). Here, ERBB2 is linked to breast carcinoma.